Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-MRD Guided Adjuvant Treatment Escalation After dCRT for Unresectable Locally Advanced ESCC
NCT07371247Phase 1Enrolling by invitation
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-Free Survival at 1 year. Started Dec 2025; status: enrolling by invitation.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07371247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371247.